We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Aberrant Expression of Cytokeratin in Plasma Cell Neoplasm.
- Authors
Hiroaki SUZUKI; Katsushige YAMASHIRO; Mitsutoshi KUROSAWA
- Abstract
It is known that cytokeratin (CK) is aberrantly expressed in a subset of plasma cell myelomas. We investigated the expression of CK (CAM5.2, AE1/AE3) in fifty consecutive cases of plasma cell neoplasms (plasma cell myeloma, n=43; solitary plasmacytoma of bone, n= 7). Seven (plasma cell myeloma, n= 5; solitary plasmacytoma of bone, n= 2) of the 50 cases were positive for CK (CAM5.2: 7/50, AE1/AE3: 0/50). The seven cases also expressed CK7 (2/7), CK8 (3/7) and CK18 (7/7) with varying intensity. One case was positive (>10%) for both CK8 and CK18 and two cases weakly expressed both CK8 and CK18 (≤10%). CK8 and CK18 are expression partners and are known to form heteropolymeric filament in cells, suggesting that heteropolymeric filament is formed in a subset of plasma cells in myeloma. On the other hand, the seven cases expressed both type I cytokeratin (CK18) and type II cytokeratin (CAM5.2). CAM5.2 primarily reacts with CK8 and to a lesser extent with CK7. Although the CK8 antibody that was used only reacted with 3 of the 7 cases, it is likely that all 7 cases expressed both CK8 and CK18. The follow-up survival data did not show a significant difference between the CAM5.2-positive group and the CAM5.2-negative group.
- Subjects
MULTIPLE myeloma; KERATIN; PLASMA cells; IMMUNOHISTOCHEMISTRY; SURVIVAL analysis (Biometry)
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2017, Vol 27, Issue 2, p69
- ISSN
1306-133X
- Publication type
Article
- DOI
10.4999/uhod.171993